W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell…
Miasta: Gliwice, Katowice, Kraków, Skórzewo i 1 inne miastoWiek: od 18 latSponsor: CSL Behring LLC
RekrutujeFaza III
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia…
Miasta: Katowice, Kielce, Kraków, Lublin i 1 inne miastoWiek: od 18 latSponsor: Grifols Therapeutics LLC
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Miasta: Białystok, Gdańsk, Katowice, Kielce i 5 innych miastWiek: od 18 latSponsor: Newave Pharmaceutical Inc.
RekrutujeFaza IV
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Miasta: Brzozów, Bydgoszcz, KatowiceWiek: od 18 latSponsor: Eli Lilly and Company
RekrutujeFaza II
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Miasta: Katowice, Kraków, Skórzewo, WarszawaWiek: od 18 latSponsor: Nurix Therapeutics Inc.
RekrutujeFaza I
A Study to Test How Safe, Effective and How the Body Responds to the Combination of Mosunetuzumab and Pirtobrutinib Together to Treat Patients with Relapsed or Refractory Chronic…
Miasta: Kraków, Lublin, WrocławWiek: od 18 latSponsor: F. Hoffmann-La Roche AG